Nephro-Urology Monthly

Published by: Kowsar

Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) as a Diagnostic Method for Prostate Cancer

Mohsen Sarkarian 1 , Alireza Kheradmand 1 , Hamed Haghiabi 2 , * and Mohammad Kolbadinezhad 2
Authors Information
1 Department of Urology, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Article information
  • Nephro-Urology Monthly: November 2018, 10 (6); e82856
  • Published Online: October 2, 2018
  • Article Type: Research Article
  • Received: August 2, 2018
  • Accepted: August 20, 2018
  • DOI: 10.5812/numonthly.82856

To Cite: Sarkarian M , Kheradmand A , Haghiabi H , Kolbadinezhad M . Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) as a Diagnostic Method for Prostate Cancer, Nephro-Urol Mon. 2018 ; 10(6):e82856. doi: 10.5812/numonthly.82856.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Aydin H, Kizilgoz V, Tatar IG, Damar C, Ugan AR, Paker I, et al. Detection of prostate cancer with magnetic resonance imaging: Optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. J Comput Assist Tomogr. 2012;36(1):30-45. doi: 10.1097/RCT.0b013e31823f6263. [PubMed: 22261768].
  • 2. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science. 1998;279(5350):563-6. [PubMed: 9438850].
  • 3. Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274(16):1277-81. [PubMed: 7563532].
  • 4. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124-37. doi: 10.1016/j.eururo.2013.09.046. [PubMed: 24207135].
  • 5. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986 - 2005. J Natl Cancer Inst. 2009;101(19):1325-9. doi: 10.1093/jnci/djp278. [PubMed: 19720969]. [PubMed Central: PMC2758309].
  • 6. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737-46. doi: 10.1056/NEJMoa1503747. [PubMed: 26244877]. [PubMed Central: PMC4562797].
  • 7. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197-209. doi: 10.1007/s00259-014-2949-6. [PubMed: 25411132]. [PubMed Central: PMC4315487].
  • 8. Tan CH, Wei W, Johnson V, Kundra V. Diffusion-weighted MRI in the detection of prostate cancer: Meta-analysis. AJR Am J Roentgenol. 2012;199(4):822-9. doi: 10.2214/AJR.11.7805. [PubMed: 22997374]. [PubMed Central: PMC3888871].
  • 9. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29(6):726-32. doi: 10.1200/JCO.2010.31.5226. [PubMed: 21205749]. [PubMed Central: PMC3056656].
  • 10. Wu LM, Xu JR, Ye YQ, Lu Q, Hu JN. The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: A systematic review and meta-analysis. AJR Am J Roentgenol. 2012;199(1):103-10. doi: 10.2214/AJR.11.7634. [PubMed: 22733900].
  • 11. Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007;189(2):323-8. doi: 10.2214/AJR.07.2211. [PubMed: 17646457].
  • 12. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: A multidisciplinary perspective. Radiology. 2007;243(1):28-53. doi: 10.1148/radiol.2431030580. [PubMed: 17392247].
  • 13. Chen M, Dang HD, Wang JY, Zhou C, Li SY, Wang WC, et al. Prostate cancer detection: Comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol. 2008;49(5):602-10. doi: 10.1080/02841850802004983. [PubMed: 18568549].
  • 14. Shimofusa R, Fujimoto H, Akamata H, Motoori K, Yamamoto S, Ueda T, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr. 2005;29(2):149-53. [PubMed: 15772529].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments